Strategic Investment Advisors MI grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,017 shares of the medical research company’s stock after purchasing an additional 25 shares during the quarter. Strategic Investment Advisors MI’s holdings in Thermo Fisher Scientific were worth $473,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dimension Capital Management LLC purchased a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $31,000. Kessler Investment Group LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at approximately $33,000. Column Capital Advisors LLC grew its holdings in Thermo Fisher Scientific by 108.3% during the 3rd quarter. Column Capital Advisors LLC now owns 75 shares of the medical research company’s stock valued at $33,000 after buying an additional 39 shares in the last quarter. Anderson Fisher LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at approximately $34,000. Finally, ARK Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at $34,000. 88.12% of the stock is currently owned by institutional investors and hedge funds.
TMO stock opened at $501.71 on Thursday. The firm’s fifty day simple moving average is $471.80 and its 200-day simple moving average is $442.37. The company has a market capitalization of $198.85 billion, a P/E ratio of 54.30, a price-to-earnings-growth ratio of 1.86 and a beta of 0.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.62 and a quick ratio of 2.02. Thermo Fisher Scientific Inc. has a 12 month low of $250.21 and a 12 month high of $532.57.
Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Thursday, November 5th that permits the company to repurchase $2.50 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.18%. The ex-dividend date is Monday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.13%.
In related news, COO Mark Stevenson sold 14,133 shares of the business’s stock in a transaction on Monday, December 7th. The shares were sold at an average price of $473.84, for a total value of $6,696,780.72. Following the completion of the transaction, the chief operating officer now directly owns 58,005 shares in the company, valued at approximately $27,485,089.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $479.94, for a total transaction of $4,799,400.00. Following the completion of the transaction, the chief executive officer now owns 228,694 shares of the company’s stock, valued at $109,759,398.36. The disclosure for this sale can be found here. Insiders sold a total of 38,246 shares of company stock worth $18,220,461 over the last ninety days. Insiders own 0.44% of the company’s stock.
TMO has been the subject of a number of recent research reports. ValuEngine upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a report on Wednesday, December 2nd. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $485.00 to $535.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $550.00 to $500.00 in a research note on Wednesday, December 16th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $488.00 price target on the stock. in a research note on Tuesday, December 22nd. Finally, SVB Leerink boosted their price target on Thermo Fisher Scientific from $470.00 to $525.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $492.58.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
Further Reading: What is Call Option Volume?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.